Skip to content
Back to meeting Original
Álvaro Pinto· @dralvaropinto · X·· 15 hours agoScore70
Body

Ivonescimab as 1L treatment for IMDC fav-risk advanced ccRCC. Promising antitumor activity, ORR 57.1%, DCR 95.2%. Manageable safety profile, TRAEs G3-4 26.9% #ESMO26

17 views · 0 likes · 0 reposts · 0 replies

Source: Álvaro Pinto · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.